Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Letue35 

Discuss Cytokinetics Inc.

Cytokinetics Inc.

WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

57,00 €
-0,87 %

Einschätzung Buy
Rendite (%) 47,67 %
Kursziel 61,52
Veränderung
Endet am 02.09.26

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 39,71 %
Kursziel 82,03
Veränderung
Endet am 02.09.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Stifel Nicolaus from $87.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 36,36 %
Kursziel 71,78
Veränderung
Endet am 02.09.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citigroup Inc. from $77.00 to $84.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 37,02 %
Kursziel 68,78
Veränderung
Endet am 03.09.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Evercore ISI from $60.00 to $80.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 37,02 %
Kursziel 61,04
Veränderung
Endet am 03.09.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Barclays PLC from $53.00 to $71.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 36,36 %
Kursziel 102,28
Veränderung
Endet am 22.09.26

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 39,02 %
Kursziel 68,18
Veränderung
Endet am 22.09.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at B. Riley from $74.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 28,38 %
Kursziel 102,37
Veränderung
Endet am 29.09.26

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 6,54 %
Kursziel 77,87
Veränderung
Endet am 10.11.26

Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at B. Riley. They now have a $90.00 price target on the stock, up previously from $80.00.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,70 %
Kursziel 75,30
Veränderung
Endet am 11.11.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $82.00 to $87.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat